NeoPhore, a cancer immune-oncology company, has formed a Scientific Advisory Board. It will be chaired by NeoPhore Scientific founder Professor Alberto Bardelli, Department of Oncology at the University of Torino, and deputy director of the Candiolo Cancer Institute-IRCCS, Torino, Italy. In addition to his role in founding NeoPhore, Professor Bardelli also co-founded Horizon Discovery and he is the president elect of the European Association for Cancer Research (EACR).

The other members of the advisory board are:

  • Luis Alberto Diaz Jr: an internationally recognized physician-scientist and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Hospital. Dr. Diaz directed clinical studies used for FDA approval of the PD-1 checkpoint inhibitor Keytruda (pembrolizumab) as indicated for any cancer with defective DNA mismatch repair.
  • Bert Vogelstein: a landmark figure in cancer research, Clayton Professor of Oncology and Pathology and Co-Director of the Ludwig Cancer at the Johns Hopkins Kimmel Cancer Center and Founder of Papgene Inc.
  • Ken Kinzler: a pioneer of cancer genetics and genomics and Professor of Oncology and Co-Director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center.
  • Ashok Venkitaraman: an international leader in cancer biology, the Ursula Zoellner Professor of Cancer Research at the University of Cambridge and the Director of the Medical Research Council (MRC) Cancer Unit.